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Every so often a new technology comes along that has the potential to significantly change 
the way patients are managed. Despite impressive early outcomes associated with 
endovascular aneurysm repair (EVAR), endoleaks and stent-graft related failure were soon 
identified as deficiencies.  Endovascular aneurysm sealing (EVAS) was developed to solve 
these problems. In general, EVAS may be considered a more straightforward procedure than 
EVAR. It involves filling the aneurysm sac with a permanent material, in an attempt to 
improve long-term durability and reduce late stent-graft related complications.  In the context 
of abdominal aortic aneurysm (AAA), stent grafts are deployed bilaterally, extending from 
the infra-renal aortic neck to the iliac arteries. Bags (‘endobags’) attached to the grafts are 
filled with liquid based polymer to obliterate residual space within the aneurysm sac 
surrounding the stent grafts. Typically, between 50-100ml of polymer is injected at supra- 
systolic blood pressure (180-220mmHg) to create a blood tight seal in the neck of the 
aneurysm and iliac arteries and contribute to stent graft stability. It cures to a permanent solid 
state within a few minutes. 
The opportunity to improve stabilisation of stent-grafts using the aortic sac remains an 
appealing idea to overcome many of the late device related failures with endovascular 
technologies, although the introduction of a stabilising agent within a stent graft delivery 
system has proved challenging. Biocompatibility, safety in the event of bag rupture and 
durability of the seal are considered essential features and critics of EVAS have suggested 
that polymer is unnecessary since thrombus within the sac after EVAR itself provides a 
stabilising effect. Concerns have been raised over rupture risk, embolization by the inflation 
of endobags at high pressure, and risk of infection posed by introducing a large volume of 
foreign body in to the AAA sac. In practice, complication rates have been very low and either 
comparable or lower than those seen after standard infra-renal EVAR 1. The risk of polymer 
leaking in to the retroperitoneum or systemic circulation appears rare although every case 
may not have been reported. 
EVAS has the potential to prevent retrograde filling of the aneurysm sac from patent side-
branches (type 2 endoleak). Efforts to prevent this type of leak during EVAR  have been 
made by  embolization of side-branches or filling the aneurysm sac with haemostatic material 
to induce sac thrombosis 2, but it has become apparent that these leaks are less dangerous 
than initially feared. Evidence from open surgical bypass and exclusion of AAA suggested 
that it was unusual to pose a clinical problem 3 and reports of sac rupture remain rare. 
Concerns about infection and neurological sequelae (embolisation through lumbar vessels) 
meant that embolisation and the introduction of embolic material in to the sac has largely 
been abandoned.  
Thrombus within the aneurysm sac is, nevertheless, biologically active. Data from the long-
term follow-up of randomised trials in AAA surgery has demonstrated an excess of  late 
deaths in patients undergoing EVAR compared with open repair. Many of these were 
cardiovascular, raising the possibility that retained thrombus within the AAA sac may play a 
role in these events. Reducing the volume of thrombus, for example by replacing it with 
polymer in EVAS might plausibly mitigate this risk 4 
The aneurysm sealing system is a simple endovascular technique that permits more rapid 
aneurysm exclusion than a bifurcated modular system, but there is a recognisable learning 
curve and there have been adaptations in technology and deployment techniques with time. 5. 
This means that there is a relative paucity of high quality published data. 
Outcomes in the industry sponsored US PIVOTAL trial and the EVAS Forward Global 
Registry seem encouraging1, 6. Technical success rates were high (99-100%) and peri-
operative mortality low (0-0.7%) with complications rates comparable to standard infra-renal 
EVAR. In the PIVOTAL trial, freedom from major adverse events was 97.3% (95% CI 93.3-
99.0) at 1 month; much lower than reported in comparative open repair cohorts. Endoleak 
rates have been low but their detection following EVAS can be difficult both on Duplex 
ultrasound and CT imaging 7. The treatment options for endoleaks and device failures post 
EVAS are often more complex and the outcomes less certain 8. 
The morphological criteria of AAA for EVAS are broadly similar to standard infra-renal 
EVAR 9. Proximal and distal landing and sealing zones are required above and below the 
aneurysmal segment. Patients with large empty (thrombus free) aneurysm sacs are currently 
unsuitable for treatment due to the capacity of the endobags. The aneurysm sealing technique 
has been complemented with visceral vessel stents in patients with more complex aortic 
morphology such as juxta-renal AAA, but as with standard infra-renal EVAR, this approach 
comes at a cost of increased secondary interventions 10.  
Iliac limb occlusion resulting in limb ischaemia remains a common problem after EVAR. 
EVAS uses a balloon expandable stent system which is somewhat less conformable to 
tortuous arteries compared to the self-expanding stents used in standard infra-renal EVAR. 
Concerns about limb occlusion in EVAS do not appear to have been borne out. Occlusion and 
re-intervention was identified in only 7 of 277 patients followed for 18 months); lower than 
many comparable EVAR series 10. One explanation for low rates of iliac limb occlusion may 
have been high rates (59% in one study) of prophylactic adjunctive re-lining of the EVAS 
limbs with additional self-expanding stents 5. 
In the EUROSTAR Registry caudal migration occurring 1-2 years after implantation of 
EVAR was a major risk factor for subsequent aortic rupture 11. Consequently many second 
and third generation  stent grafts evolved to include more robust fixation systems including 
hooks and barbs placed either in the aortic neck or the relatively disease free supra-renal 
aorta. EVAS does not rely on these fixation systems but instead on the stents and polymer as 
well as the integrity of the aneurysm sac. The data on migration rates are sparse but one 
recent small study suggested these may be concerning (28% at 12months follow-up)12. 
The challenge now is to gain more information about EVAS so that if it is to be widely 
adopted, this is based on high quality evidence regarding safety, success and complication 
rates  and economic considerations. When considered in the context of the IDEAL guidance, 
EVAS is now probably at IDEAL stage 2a 13 and this means reporting how patients are 
selected for the new treatment, what other treatments are offered to patients with similar 
characteristics within the same time frame and why. It requires transparent reporting of 
outcomes (whether positive or negative) and details about how and why the intervention is 
modified as experience is gained with it. IDEAL also recommends that ethical approval is 
obtained to ensure patients receive full informed consent about the novel intervention – with 
documentation of the information provided, to protect patients and surgeons from known and 
unknown adverse events associated with a new technique. Following this approach allows 
patients to make informed choices about whether to participate in early phase studies or to 
select standard treatments 14. It follows that a system of compulsory registration should be in 
place, to ensure that wider adoption of this technology is truly evidence-based. 
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